Every 8-K that aTyr Pharma, Inc. (ATYR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATYR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATYR filings page.
aTyr Pharma reported second quarter 2026 results and a major restructuring to prioritize its efzofitimod program for interstitial lung disease. Operating expenses were $10.9 million, including research and development of $6.7 million and general and administrative of $4.1 million, leading to a net loss attributable to aTyr of $10.3 million, or $0.11 per share, compared with $19.5 million, or $0.22 per share, a year earlier. Cash, cash equivalents, restricted cash and investments were $58.9 million as of June 30, 2026.
The company plans a workforce reduction of approximately 60% and other cost-saving measures it expects will reduce annualized operating expenses by about $13 million beginning in the fourth quarter of 2026 and support a cash runway into late 2028 while focusing resources on efzofitimod. Chief Financial Officer Jill Broadfoot and General Counsel Nancy Denyes will step down on September 30, 2026 and transition to consulting roles; Vice President of Finance Brandon Yaras will become CFO on October 1, 2026.
aTyr is awaiting U.S. Food and Drug Administration feedback by the end of August 2026 on a protocol for a planned global Phase 3 study of efzofitimod in pulmonary sarcoidosis and has completed enrollment in the Phase 2 EFZO-CONNECT study in SSc-ILD, with topline data expected in the first quarter of 2027.
aTyr Pharma, Inc. entered into a Termination Agreement with Kyorin Pharmaceutical Co., Ltd. effective July 30, 2026, formally ending their 2020 collaboration and license arrangement for efzofitimod in Japan. All licenses Kyorin held under the prior agreement, including exclusive rights to develop and commercialize efzofitimod for interstitial lung disease in Japan, ceased on the termination date, and those exclusive territorial rights reverted to aTyr. As a result, aTyr now holds the right to develop and commercialize efzofitimod globally.
Under the agreement, Kyorin grants aTyr worldwide, irrevocable, perpetual, royalty‑free licenses to Kyorin Background Technology (non‑exclusive) and to New Kyorin IP and Kyorin’s interest in New Joint IP (exclusive) related to the Reversion Products. Kyorin will transfer extensive clinical, regulatory and manufacturing data, including Handover Documents and Essential Documents, and will assign to aTyr the Japanese orphan drug designation for efzofitimod, while continuing certain sponsor responsibilities and archival obligations during a transition period of up to twelve (12) months. The parties mutually release claims under the prior collaboration arising before the termination date and confirm there are no outstanding development cost payments owed by Kyorin to aTyr.
aTyr Pharma, Inc. received an additional 180-day period from Nasdaq to regain compliance with the exchange’s minimum bid price requirement for continued listing. The company now has until November 30, 2026 for its stock to close at or above $1.00 for at least 10 consecutive business days.
The extension was granted because aTyr meets other Nasdaq Capital Market listing standards, including market value of publicly held shares, and has stated its intention to cure the deficiency, potentially through a reverse stock split. The company’s shares remain listed while it monitors its stock price and evaluates options.
aTyr Pharma furnished an investor presentation outlining updated clinical data and plans for its lead biologic immunomodulator efzofitimod in pulmonary sarcoidosis and other interstitial lung diseases. The Phase 3 EFZO-FIT trial, the largest interventional pulmonary sarcoidosis study to date, did not meet its primary endpoint of reducing oral corticosteroid dose versus placebo, but showed higher steroid-free rates and improvements in multiple quality-of-life measures at the 5 mg/kg dose while maintaining lung function and a generally favorable safety profile.
The company describes FDA feedback from a Type C meeting supporting forced vital capacity (FVC) and KSQ-L as clinically meaningful endpoints, with FVC selected as the primary endpoint for a new Phase 3 trial (C-006) in patients with restrictive pulmonary sarcoidosis. Efzofitimod is also being tested in the Phase 2 EFZO-CONNECT study for systemic sclerosis-associated ILD and supported by a broader tRNA synthetase–based pipeline, including preclinical fibrosis candidate ATYR0101 and a proprietary tRNA synthetase library targeting inflammatory and fibrotic diseases.
aTyr Pharma, Inc. reported first quarter 2026 results and outlined next steps for its lead drug efzofitimod in interstitial lung disease. The company plans to submit an IND in June 2026 for a global Phase 3 pulmonary sarcoidosis study and is on track to complete enrollment in its Phase 2 EFZO-CONNECT SSc-ILD trial in the first half of 2026.
aTyr ended the quarter with $68.3 million in cash, cash equivalents, restricted cash and investments. Net loss attributable to aTyr was $10.8 million, compared with $14.9 million a year earlier, with net loss per share of $0.11 versus $0.17 in 2025. Research and development expenses were $7.3 million and general and administrative expenses were $4.1 million for the quarter.
aTyr Pharma reported preliminary cash, cash equivalents, restricted cash and available-for-sale investments of $68.3 million as of March 31, 2026, and outlined a new pivotal plan for its lead drug efzofitimod in pulmonary sarcoidosis.
Following a Type C meeting with the FDA, the company plans a new global Phase 3 trial in chronic, symptomatic pulmonary sarcoidosis patients with restrictive lung disease, using change in forced vital capacity (FVC) at week 48 as the primary endpoint and the King’s Sarcoidosis Questionnaire-Lung score as the key secondary endpoint.
The 54-week study is expected to enroll about 372 patients on stable low-dose steroids and/or immunosuppressants, with efzofitimod 5.0 mg/kg or placebo given intravenously every three weeks for 17 doses. aTyr intends to file an IND for this C-006 study in June 2026, incorporating enhanced safety monitoring and risk mitigation measures.
aTyr Pharma reported fourth quarter and full year 2025 results and provided a pipeline update centered on its lead drug efzofitimod for interstitial lung diseases.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48, but the 5.0 mg/kg dose showed clinical benefits on several pre-specified measures of symptoms and quality of life, and maintained lung function with a favorable safety profile. The company has a Type C meeting with the FDA scheduled for mid-April 2026 to review the data and determine the regulatory path forward.
aTyr’s Phase 2 EFZO-CONNECT trial in systemic sclerosis-related interstitial lung disease is on track to complete enrollment in the first half of 2026. The company also highlighted preclinical progress for ATYR0101 in fibrosis and published research on a bispecific NRP2/PLXNA1 antibody with potential anticancer activity. For 2025, aTyr generated $190 thousand in collaboration revenue, incurred $60.2 million in research and development expenses and $17.6 million in general and administrative expenses, leading to a net loss attributable to aTyr of $74.1 million, or $0.80 per share. Cash, cash equivalents, restricted cash and investments totaled $80.9 million as of December 31, 2025.
aTyr Pharma (ATYR) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to an Item 2.02 Form 8-K. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.
aTYR Pharma reported results from a 268-patient global Phase 3 study in pulmonary sarcoidosis comparing efzofitimod 3.0 mg/kg and 5.0 mg/kg versus placebo over 48 weeks with a protocol-guided steroid taper. The primary steroid-reduction endpoint showed mean daily oral corticosteroid (OCS) doses of 2.79 mg for 5.0 mg/kg efzofitimod versus 3.52 mg for placebo (p=0.3313), which was not statistically significant. Secondary measures showed a statistically significant improvement in KSQ-Lung score for 5.0 mg/kg (change 10.36 vs 6.19; p=0.0479) and a higher rate of complete steroid withdrawal with KSQ-Lung improvement (29.5% vs 14.4%; p=0.0199). Change in FVC was similar between groups (−1.81 vs −2.11; p=0.7875). Treatment was generally well tolerated at both doses.